Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]
Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.
1.
Common intracellular toxin could help fight leukemia
2.
One-third of childhood cancer survivors experience significant fear that it could come back, study reveals
3.
Children living near oil and gas wells face higher risk of rare leukemia, studies show
4.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
5.
RML to develop bone marrow transplantation at Lady Hardinge Medical College in Safdarjung
1.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
2.
Can We Repurpose BV-CHP for Better Outcomes in Peripheral T-Cell Lymphoma?
3.
Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy
4.
Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer
5.
Transfusing the Future: Exploring the Possibilities of Blood Transfusions
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge